Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-0276 in Moderate to Severe Psoriasis
NCT07204639Phase 2Recruiting
- Sponsor
- Clarent Biopharma Inc
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of CBP-0276 in plaque psoriasis, sponsored by Clarent Biopharma Inc. Started Oct 2025; status: recruiting.
02
Drugs
CBP-0276
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07204639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204639.